Convection Enhanced Delivery in the Setting of High-Grade Gliomas

• Type of Material: Article
• Authors: Chibueze D. Nwagwu, Emory University; Amanda V. Immidisetti, Rutgers State University; Michael Y. Jiang, Imperial College London; Oluwasegun Adeagbo, Emory University; David Adamson, Emory University; Anne-Marie Carbonell, OncoSynergy Inc
• Language: English
• Date: 2021-04-01
• Publisher: MDPI
• Publication Version: Final Published Version
• Copyright Statement: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.3390/pharmaceutics13040561
• Title of Journal or Parent Work: Pharmaceutics
• Volume: 13
• Issue: 4
• Grant/Funding Information: This research received no external funding.
• Keywords: refractory glioblastoma; direct delivery; glioblastoma; Life Sciences & Biomedicine; Trial; refractory glioma; neuro-oncology; Targeted toxin; Safety; Phase-I; Paclitaxel; clinical trials; Intracerebral haemorrhage; high-grade glioma; Pharmacology & Pharmacy; convection enhanced delivery; Infusion; Science & Technology; Gene-therapy; Glioblastoma
• Research Categories: Biology, Genetics; Biology, Neuroscience; Health Sciences, Oncology; Health Sciences, Pharmacology

Abstract

Development of effective treatments for high-grade glioma (HGG) is hampered by (1) the blood–brain barrier (BBB), (2) an infiltrative growth pattern, (3) rapid development of therapeutic resistance, and, in many cases, (4) dose-limiting toxicity due to systemic exposure. Convection-enhanced delivery (CED) has the potential to significantly limit systemic toxicity and increase therapeutic index by directly delivering homogenous drug concentrations to the site of disease. In this review, we present clinical experiences and preclinical developments of CED in the setting of high-grade gliomas.